Treffer 1 - 7 von 7 für Suche 'Altzerinakou, Maria‐Athina', Suchdauer: 0,93s Treffer weiter einschränken
  1. 1
    Change‐point joint model for identification of plateau of activity in early phase trials

    Change‐point joint model for identification of plateau of activity in early phase trials von Altzerinakou, Maria‐Athina, Paoletti, Xavier

    Veröffentlicht in Statistics in medicine

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose

    Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose von Altzerinakou, Maria-Athina, Collette, Laurence, Paoletti, Xavier


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  3. 3
    An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology

    An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials... von Altzerinakou, Maria-Athina, Paoletti, Xavier


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  4. 4
    Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

    Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG al... von Grell, Peter, Lin, Chia-Chi, Milella, Michele, Chee, Cheng Ean, Sivakumar, Shivan, Peltola, Katriina Johanna, Bostel, Geraldine, Jankovic, Dragana, Altzerinakou, Maria-Athina, Fabre, Claire, Santoro, Armando

    Veröffentlicht in Journal of clinical oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  5. 5
    Phase II study (daNIS-1) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

    Phase II study (daNIS-1) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) ve... von Bai, Li-Yuan, Macarulla, Teresa, Grell, Peter, Chee, Cheng Ean, Krishnamurthy, Anuradha, Wong, Mark Ka, Michael, Michael, Milella, Michele, Prager, Gerald, Springfeld, Christoph, Collignon, Joelle, Siveke, Jens, Santoro, Armando, Lin, Chia-Chi, Peltola, Katriina Johanna, Bostel, Geraldine, Jankovic, Dragana, Altzerinakou, Maria-Athina, Fabre, Claire, Sivakumar, Shivan

    Veröffentlicht in Journal of clinical oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  6. 6
    Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

    Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) ve... von Bai, Li-Yuan, Macarulla, Teresa, Grell, Peter, Chee, Cheng Ean, Krishnamurthy, Anuradha, Wong, Mark Ka, Michael, Michael, Milella, Michele, Prager, Gerald, Springfeld, Christoph, Collignon, Joelle, Siveke, Jens, Santoro, Armando, Lin, Chia-Chi, Peltola, Katriina Johanna, Bostel, Geraldine, Jankovic, Dragana, Altzerinakou, Maria-Athina, Fabre, Claire, Sivakumar, Shivan

    Veröffentlicht in Journal of clinical oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  7. 7
    Méthodes statistiques pour les essais de phase I/II de thérapies moléculaires ciblées en cancérologie

    Méthodes statistiques pour les essais de phase I/II de thérapies moléculaires ciblées en cancérologie von Altzerinakou, Maria Athina

    Volltext bestellen
    Dissertation

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: